Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Advocacy groups sits at the center of this dementia and brain health question.
Advocacy groups representing Alzheimer’s disease patients, caregivers, and researchers have been actively engaging with lawmakers to push for increased federal funding for Alzheimer’s and dementia research and care services. These meetings represent a critical effort to secure government support at a time when the prevalence of Alzheimer’s disease continues to rise, affecting an estimated 6.9 million Americans—a number that could nearly triple by 2060 if current trends continue. In early 2024, organizations like the Alzheimer’s Association and UsAgainstAlzheimer’s met with congressional representatives to advocate for funding increases in the National Institutes of Health’s Alzheimer’s research programs, which currently receive approximately $3.4 billion annually but require substantially more resources to match the disease’s public health impact.
These advocacy efforts highlight the gap between current research investment levels and the actual burden of Alzheimer’s disease on patients and the American healthcare system. The disease is projected to cost the nation over $1 trillion annually in care costs within the next decade, yet federal research funding has not kept pace with this growing epidemic. Advocates argue that increased investment in research could accelerate the development of new treatments and preventive strategies, while additional funding for support services could improve quality of life for millions of people living with dementia and their family caregivers who provide 18 billion unpaid hours of care each year.
Table of Contents
- What Are Advocacy Groups Asking Lawmakers to Fund?
- The Current State of Alzheimer’s Funding and Its Limitations
- How Lawmakers Are Responding to Advocacy Efforts
- Practical Ways Caregivers Can Support Advocacy Efforts
- Challenges in Translating Advocacy to Policy Change
- International Comparisons in Dementia Funding
- Future Outlook for Alzheimer’s Funding and Advocacy
- Conclusion
- Frequently Asked Questions
What Are Advocacy Groups Asking Lawmakers to Fund?
Advocacy organizations seeking increased Alzheimer’s funding are not asking for a single initiative but rather a comprehensive increase across multiple priority areas. These include expanding basic research into the biological mechanisms of Alzheimer’s disease, funding clinical trials to test promising new therapies, supporting the development of biomarkers that could enable early detection, and financing programs that provide respite care, counseling, and support for family caregivers. The Alzheimer’s Association, for example, has called for lawmakers to increase NIH funding specifically designated for Alzheimer’s research to at least $8 billion annually—roughly double the current allocation.
The requests reflect a strategic approach that recognizes both the urgent need for better treatments and the immediate need for services that help people manage the disease today. While pharmaceutical research aims for long-term solutions, funding for caregiver support and care services addresses the pressing reality that people with Alzheimer’s need help now. This dual approach is essential because even as scientists work toward breakthrough treatments, current patients and caregivers face significant financial and emotional burdens. The American Academy of Neurology has similarly emphasized the need for funding that supports both the discovery pipeline and the clinical infrastructure required to deliver effective care.
The Current State of Alzheimer’s Funding and Its Limitations
Federal Alzheimer’s funding has increased modestly over the past decade, but it remains disproportionately small relative to the disease’s prevalence and cost. For comparison, federal funding for cancer research exceeds $7 billion annually, while Alzheimer’s research receives less than half that amount—despite Alzheimer’s being the sixth leading cause of death in the United States and the only major disease without a way to slow, stop, or prevent its progression. This funding gap represents a critical limitation in the research landscape, as it means fewer studies can be conducted and promising research projects cannot receive support.
The limitation extends to research areas that might seem obvious but remain underfunded. For example, there is relatively little federally funded research exploring why women account for nearly two-thirds of Alzheimer’s disease cases, or why African Americans and Hispanic populations experience higher rates of cognitive decline. These research gaps mean that treatments and prevention strategies being developed may not adequately address the needs of communities bearing the heaviest burden of disease. Additionally, many research proposals that show scientific promise are rejected simply due to lack of funding, creating what researchers call the “funding ceiling” effect where innovation is constrained not by scientific capability but by available resources.
How Lawmakers Are Responding to Advocacy Efforts
Congressional responses to Alzheimer’s advocacy have been mixed but generally supportive in principle. Both major political parties have recognized Alzheimer’s disease as a public health priority, and several bills aimed at increasing funding and supporting research have been introduced in recent congressional sessions. The Build Back Better initiative that passed in modified form included provisions for senior care that touched on dementia services, demonstrating that Alzheimer’s funding can gain bipartisan support when framed as an aging population issue.
However, advocacy groups note that symbolic support often falls short of meaningful action. While lawmakers agree that more funding is needed, translating this agreement into budget allocations remains challenging due to competing priorities and fiscal constraints. Some representatives have championed specific funding increases—members of Congress from districts with high concentrations of Alzheimer’s cases tend to be more active advocates—but sustained, coordinated pressure is required to move funding proposals through the appropriations process. The Alzheimer’s Impact Movement, for example, runs a sophisticated campaign that includes constituent visits, testimony before congressional committees, and coordination with patient and caregiver networks to keep Alzheimer’s funding on lawmakers’ radar.
Practical Ways Caregivers Can Support Advocacy Efforts
Families and caregivers affected by Alzheimer’s disease have significant power to influence funding decisions by directly engaging with their elected representatives. This can be as simple as contacting your congressional representative’s office to express support for increased Alzheimer’s research and care funding, or attending town halls and asking about their position on dementia care investments. Many advocacy organizations provide templates and talking points to make this advocacy accessible, even for people managing the demands of caregiving.
More intensive involvement includes joining advocacy organizations’ legislative initiatives, signing petitions, and participating in awareness campaigns during National Alzheimer’s Awareness Month in November. Some caregivers find that sharing their personal stories with lawmakers is particularly powerful—the realities of providing care without adequate support, the financial strain of out-of-pocket expenses, and the emotional toll of the disease create a compelling narrative that statistics alone cannot convey. This approach has a tangible advantage: personal testimony influences policy in ways that abstract funding arguments often cannot, which is why advocacy organizations actively encourage caregivers to share their experiences with elected officials.
Challenges in Translating Advocacy to Policy Change
Despite sustained advocacy efforts, translating increased calls for funding into actual budget increases faces significant obstacles. One major limitation is that federal budget discussions involve countless competing priorities—healthcare, infrastructure, defense, education—all vying for limited resources. Alzheimer’s advocates must make a compelling case that their issue deserves priority relative to other pressing needs, a argument that becomes harder during periods of fiscal austerity or economic uncertainty. Additionally, even when funding increases are approved, implementation can lag by months or years, delaying the actual availability of new resources for researchers and caregivers.
Another challenge is the complexity of the appropriations process itself. Funding decisions don’t happen in a single vote but rather through a series of budget bills, committee negotiations, and procedural steps that advocacy groups must navigate and influence at each stage. A warning worth noting: organizations that focus advocacy efforts narrowly on a single bill or legislative session may miss critical opportunities to influence funding through other pathways, such as direct agency budget requests or earmarked funding proposals. This is why sustained, year-round advocacy is more effective than occasional campaigns tied to specific legislative windows.
International Comparisons in Dementia Funding
Looking beyond the United States, other developed nations have made different policy choices regarding dementia research and care funding. Some European countries allocate higher percentages of their healthcare budgets to dementia services, resulting in more robust caregiver support systems and earlier access to diagnostic services. For example, the United Kingdom’s National Health Service funds dementia diagnosis and post-diagnostic support through primary care, reducing the financial burden on families compared to the American system where many services are out-of-pocket. However, these international comparisons also reveal trade-offs.
Countries with high dementia care spending often have different healthcare financing systems, higher overall tax burdens, and different prioritization strategies. The takeaway for U.S. advocacy is not that we should simply copy other nations’ approaches but rather that funding models exist that provide more comprehensive support—evidence that increased U.S. investment in dementia services is a realistic policy goal, not an impossible dream.
Future Outlook for Alzheimer’s Funding and Advocacy
As the population ages and Alzheimer’s prevalence increases, the pressure for increased federal funding is expected to intensify. Demographic trends are on the side of advocates: the number of Americans aged 65 and older is projected to reach 94.7 million by 2060, with the fastest growth among those aged 85 and older—the group most at risk for Alzheimer’s disease.
This changing demographic landscape means that Alzheimer’s will become an increasingly visible and pressing issue for voters and their families, likely increasing political will for funding increases. Looking forward, successful advocacy will likely need to broaden beyond research funding to include comprehensive policy changes—such as Medicare coverage for cognitive testing, paid family leave for dementia caregivers, and regulatory changes that speed the approval process for new therapies. Organizations like the Alzheimer’s Association are already positioning themselves around these broader policy goals, recognizing that funding increases alone will not solve the crisis without accompanying changes to how the healthcare system delivers care and supports families.
Conclusion
The advocacy efforts by Alzheimer’s disease organizations represent a crucial engagement with the policy process, bringing attention to chronic underfunding of research and caregiver support at a time when the disease’s prevalence and impact continue to grow. While congressional representatives have shown general support for increased Alzheimer’s funding, translating that support into substantial budget increases requires sustained, multifaceted advocacy that engages patients, caregivers, researchers, and the public. The gap between current federal funding levels and the actual scope of the disease burden remains stark, and closing that gap will require continued pressure from advocacy groups and participation from affected families.
For individuals and families dealing with Alzheimer’s disease, engagement in advocacy efforts offers both a concrete way to influence policy and a sense of agency in facing a disease that can otherwise feel overwhelming. Whether through contacting elected representatives, supporting advocacy organizations, or sharing personal stories, caregivers can contribute to building the political will necessary to increase funding. As demographic trends make Alzheimer’s disease an issue affecting an increasing proportion of American families, the foundation for sustained funding increases is gradually being built—but realizing that potential will depend on continued advocacy and public engagement.
Frequently Asked Questions
How much federal funding does Alzheimer’s research currently receive?
Federal funding for Alzheimer’s research through the National Institutes of Health is approximately $3.4 billion annually. Advocacy groups are calling for this amount to be roughly doubled to at least $8 billion to match the disease’s prevalence and impact.
Who are the main advocacy groups working on Alzheimer’s funding?
Major organizations include the Alzheimer’s Association, UsAgainstAlzheimer’s, the American Academy of Neurology, and the Alzheimer’s Impact Movement. These groups organize advocacy campaigns, meet with lawmakers, and mobilize caregivers to support funding increases.
How can I contact my representative about Alzheimer’s funding?
You can find your congressional representative on House.gov or Senate.gov, then contact their office through phone, email, or in-person visits. Many Alzheimer’s advocacy organizations provide talking points and guidance to help you draft an effective message.
What specific areas of Alzheimer’s research are most underfunded?
Research on why women are disproportionately affected by Alzheimer’s, disparities in disease rates among African American and Hispanic populations, and biomarker development for early detection are among the areas that receive relatively little funding compared to their scientific importance.
What is the difference between advocacy for research funding and advocacy for care services funding?
Research funding supports laboratory and clinical work aimed at developing new treatments and understanding disease mechanisms. Care services funding supports immediate needs like respite care, caregiver support, and counseling services for people currently living with Alzheimer’s and their families.
You Might Also Like
- Benefit Concerts and Entertainment Events Fund Alzheimer’s Research
- Team-Based Fundraising Events Build Community Around Alzheimer’s Cause
- Scientific Publication Trends Reflect Growing Alzheimer’s Research Activity
For more, see Alzheimer’s Association — medical tests.
